Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Theravance Biopharma, Inc. (TBPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 SC 13D/A Weiss Asset Management LP reports a 14.1% stake in Theravance Biopharma, Inc.
08/11/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update",
"MEDICINES THAT MAKE A DIFFERENCE"
07/14/2023 144 Form 144 - Report of proposed sale of securities:
07/10/2023 SC 13G/A Baupost Group reports a 12.8% stake in Theravance Biopharma, Inc.
06/09/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
06/08/2023 144 Form 144 - Report of proposed sale of securities:
05/15/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update",
"Slide deck entitled First Quarter 2023 Financial Results and Business Update"
05/03/2023 8-K Quarterly results
04/17/2023 8-K Quarterly results
04/14/2023 144 Form 144 - Report of proposed sale of securities:
03/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/17/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/01/2023 10-K Annual Report for the period ended December 31, 2022
03/01/2023 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
02/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
02/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Continued Transformation Positions Theravance Biopharma for Value Creation"
02/27/2023 8-K Quarterly results
Docs: "Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update",
"Slide deck entitled Strategic Actions and Fourth Quarter / Full Year 2022 Financial Results and Business Update"
02/14/2023 SC 13G/A ORBIMED ADVISORS LLC reports a 0% stake in Theravance Biopharma, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 8.2% stake in Theravance Biopharma Inc.
01/30/2023 SC 13G BARCLAYS PLC reports a 5% stake in THERAVANCE BIOPHARMA, INC.
01/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets",
"Slide deck entitled Theravance Biopharma Investor Presentation"
12/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/22/2022 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
11/18/2022 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy